LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

Home・Elenco Azioni・Fate Therapeutics Inc

Fate Therapeutics Inc

Aperta

SettoreSettore sanitario

2.18 -3.54

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.1

Massimo

2.26

Metriche Chiave
By Trading Economics
Entrata	1.2M -31M
Vendite	-70K 1.3M
EPS	-0.26
Margine di Profitto	-2,402.848
Dipendenti	161
EBITDA	12M -30M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+96.44% upside

Dividendi
By Dow Jones
Utili prossimi	10 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-52M 202M
Apertura precedente	5.72
Chiusura precedente	2.18

Notizie sul Sentiment di mercato

By Acuity

77%

23%

317 / 345 Classifica in Healthcare

Fate Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

25 mag 2026, 08:24 UTC

I principali Market Mover

Acquisizioni, Fusioni, Takeovers

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 mag 2026, 21:22 UTC

Utili

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 mag 2026, 20:50 UTC

Discorsi di Mercato

Utili

Basic Materials Roundup: Market Talk

25 mag 2026, 16:20 UTC

Discorsi di Mercato

Utili

Basic Materials Roundup: Market Talk

25 mag 2026, 16:01 UTC

Discorsi di Mercato

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 mag 2026, 14:43 UTC

Discorsi di Mercato

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 mag 2026, 14:15 UTC

Discorsi di Mercato

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 mag 2026, 13:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

25 mag 2026, 12:58 UTC

Discorsi di Mercato

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 mag 2026, 12:56 UTC

Discorsi di Mercato

Utili

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 mag 2026, 12:48 UTC

Discorsi di Mercato

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 mag 2026, 12:48 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

25 mag 2026, 12:34 UTC

Discorsi di Mercato

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 mag 2026, 12:10 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Delivery Hero's Assets Look Strategic -- Market Talk

25 mag 2026, 11:00 UTC

Discorsi di Mercato

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 mag 2026, 10:19 UTC

Discorsi di Mercato

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 mag 2026, 10:05 UTC

Utili

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 mag 2026, 10:04 UTC

Utili

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 mag 2026, 10:03 UTC

Utili

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 mag 2026, 10:02 UTC

Utili

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 mag 2026, 10:01 UTC

Utili

Tenaga Nasional 1Q Net Up 3.7% on Year

25 mag 2026, 10:00 UTC

Utili

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional 1Q EPS MYR0.1883

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional 1Q Rev MYR17.1B

25 mag 2026, 09:56 UTC

Utili

Tenaga Nasional 1Q Net MYR1.1B

25 mag 2026, 09:38 UTC

Discorsi di Mercato

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 mag 2026, 09:33 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

25 mag 2026, 09:33 UTC

Discorsi di Mercato

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 mag 2026, 08:55 UTC

Discorsi di Mercato

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Confronto tra pari

Modifica del prezzo

Fate Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

96.44% in crescita

Previsioni per 12 mesi

Media 4.42 USD 96.44%

Alto 7 USD

Basso 2.2 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Fate Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Fate Therapeutics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

317 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.